Novacyt Announces Bond Issue

Novacyt – Announces Bond Issue ENG Paris, France and Cambridge, UK – 6th April 2017 – Novacyt (ALTERNEXT: ALNOV), an international specialist in clinical diagnostics, today announces the Company has issued a convertible bond in the amount of €1,500,000 through the issuance of 1,500,000 bonds which are convertible into shares with a nominal value of

Visit Page

MDxHealth Signs Agreement with Lab21 to Make SelectMDx Liquid Biopsy Test Available in the United Kingdom

IRVINE, CA, and HERSTAL, BELGIUM – March 21, 2017 – MDxHealth SA (Euronext: MDXH.BR), today announced that it has signed a distribution agreement to make its SelectMDx™ for Prostate Cancer test available to Lab21 Clinical Laboratory’s urology clients in the United Kingdom. MDxH-Lab 21 agreement PR ENG

Visit Page

Novacyt provides an R&D update on its initial molecular products pipeline

R&D Strategy Update PR ENGLISH Paris, France and Cambridge, UK – 5th September 2016 – Novacyt (ALTERNEXT: ALNOV), an international clinically focused diagnostics company, today provides a Research and Development (R&D) update following the completion of the acquisition of Primerdesign in May 2016. The integration of Primerdesign is progressing well, in line with the strategic

Visit Page